A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia ...

Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth ...

Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...

The results could pave the way for Pfizer’s drug ponsegromab to become the first-ever approved treatment specifically for ...

Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer cells, which is called cachexia, Pfizer said in a news release Saturday.

The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...